We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • Topics
  • Nutra-Q Directory
  • Magazine
  • e-Learning Tools
  • Advertise

Modern Medicine Network
  • Login
  • Register
Skip to main content
  • Login
  • Register
Menu
User
Home
  • Topics
  • Nutra-Q Directory
  • Magazine
  • e-Learning Tools
  • Advertise

SUBSCRIBE: eNewsletter | Magazine

ProbioKid Strains Safe, Well-Tolerated, Study Confirms

  • Photo © iStockphoto.com/shironosov
  • Jennifer Prince
Aug 7, 2017
  • Digestive Health, Science

Lallemand Health Solutions (Montreal) announced the results of a new study, published in Beneficial Microbes,1 confirming the safety and tolerability of three probiotic strains in healthy infants. The study, which was conducted by a team from Madrid University (Spain) and funded by Lallemand, found that the three probiotic strains present in Lallemand’s ProbioKid formula—Lactobacillus helveticus Rosell-52, Bifidobacterium infantis Rosell-33, and Bifidobacterium bifidum Rosell-71—were safe and well-tolerated.

According to the company, the aim of this study was to build on the substantial existing research and further establish the safety and tolerability of the strains. It noted that the ProbioKid formula and the individual strains recently obtained GRAS status in the U.S., and were also approved by Health Canada for children from three months old. The new study follows the “track record of safe use,” and “reinforces the assurance we have in our product,” said Bérengère Feuz, marketing group manager, Lallemand, in a press release.

The randomized, double-blind, placebo-controlled intervention study was conducted over a period of 12 weeks, with eight weeks of treatment. Researchers recruited 221 healthy infants between the ages of three and 12 months, and the subjects were then split into four groups. Three of the groups were given one of Lallemand’s three ProbioKid probiotic strains (3x109 colony-forming units, or CFU) daily, while the fourth group received an equivalent dose of a placebo and served as the control. Key areas of safety evaluation included growth (weight, height, and head circumference), adverse or serious adverse events, concentration of D-lactic acid in urine samples, characteristics of stools, and use of medication.

Pediatricians recorded measurements for all criteria over the course of four visits: one at the start of the study, a second at the end of the two-week run-in period, a third following the eight-week treatment period, and the last at the end of the two-week follow-up period. By the end of the study period, the study authors found no adverse or serious adverse events, and weight, length, and head circumference growth was consistent across all four groups. Per the study, “the changes in anthropometric measures showed equivalence for each of the three treatment groups when compared to the placebo,” leading the authors to conclude that the probiotics do not have any effect on growth. Finally, the concentration of D-lactic acid measured in urine samples were below the quantification limit, and stool characteristics were equivalent across all groups.

Of the study results, Feuz said: “We are very impressed by the quality and impact of this very well-designed study as it involves a large population of healthy infants and assesses independently each of the individual strains.” She added that the results of the study will also be used to conduct a secondary analysis with the goal of providing additional information about each strain’s interactions with the microbiota and immune system.

References: 
  1. Manzano S et al. “Safety and tolerability of three probiotics strains in health infants. A multi-centre randomized, double-blind, placebo-controlled trial.” Beneficial Microbes. Published online May 30, 2017. 

Related Articles

  • Piperine, Curcumin Complex Reduces Total Body Fat in Animal Study
  • Lipid-Encapsulated Curcumin Provides Greater Anti-Inflammatory, Neuroprotective Benefits than Unformulated Curcumin in Animal Study
  • Joint-Health Botanical Extract Blend Reduced Muscle Soreness, Supported Exercise Recovery, in New Study, Company Says
  • UC-II Collagen Reduces Cartilage Deterioration in Animal Study
  • Mung Bean Protein Isolate May Improve Insulin Response, Reduce Fat Accumulation

Fun Facts

Fun Fact!

Weekly Fun Facts about nutrition and ingredients, courtesy of Nutritional Outlook's editors

Current Issue

Nutritional Outlook Vol. 21, No 3
Apr 01, 2018 Vol 21 No 3
Digital Edition
Connect with Us
  • Twitter
  • Facebook
  • Google+
  • LinkedIn
  • RSS
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.